Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clomethiazole→

Clomethiazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
533-45-9
Molecular formula
C6H8ClNS
Molecular weight
161.65 g/mol
Drug class
Thiazole sedative-hypnoticpositive allosteric modulator of GABAA receptors
Mechanism of action
Enhances GABA-mediated inhibitory neurotransmission through actions at GABAA receptor complexes and may also affect glycine-mediated inhibition. It produces sedative, hypnotic and anticonvulsant effects.
Indications / reported uses
  • Short-term treatment of severe agitation and alcohol withdrawal symptoms in selected hospital settings in countries where clomethiazole is authorised
  • Historically used for short-term insomnia in selected patients; it carries respiratory-depression and dependence risks and is not a routine long-term hypnotic
View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Clomethiazole Environmental Risk Assessment (ERA) (the Clomethiazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.